Cytokinetics, Inc.  

(Public, NASDAQ:CYTK)   Watch this stock  
Find more results for CYTK
+0.40 (5.00%)
Dec 15 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.00 - 8.45
52 week 7.00 - 17.20
Open 8.05
Vol / Avg. 2.55M/1.15M
Mkt cap 475.26M
P/E     -
Div/yield     -
EPS -1.66
Shares 53.88M
Beta 1.61
Inst. own 75%
Feb 14, 2018
Q4 2017 Cytokinetics Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 21, 2017
Cytokinetics Inc to Discuss Phase 3 Clinical Trial of Tirasemtiv in Patients with ALS Conference Call
Oct 26, 2017
Q3 2017 Cytokinetics Inc Earnings Call - Webcast
Oct 26, 2017
Q3 2017 Cytokinetics Inc Earnings Release
Sep 26, 2017
Cytokinetics Inc at Cantor Fitzgerald Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -523.58% 15.46%
Operating margin -459.94% 17.56%
EBITD margin - 18.26%
Return on average assets -38.92% 11.53%
Return on average equity -80.60% 20.19%
Employees 127 -
CDP Score - -


280 E Grand Ave
United States - Map
+1-650-6243000 (Phone)
+1-650-6243010 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates, which are in clinical development include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its tirasemtiv and CK-2127107 are skeletal muscle troponin activators. It is developing tirasemtiv drug candidate for the treatment of Amyotrophic lateral sclerosis (ALS). The Company is developing CK-2127107 for the potential treatment of spinal muscular atrophy, chronic obstructive pulmonary disease and ALS. The Omecamtiv mecarbil is a cardiac muscle myosin activator, which is being evaluated for the treatment of heart failure.

Officers and directors

Leonard Patrick Gage Ph.D. Independent Chairman of the Board
Age: 74
Bio & Compensation  - Reuters
Robert I. Blum President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Ching Jaw Chief Financial Officer, Senior Vice President
Age: 54
Bio & Compensation  - Reuters
Sharon A. Barbari Executive Vice President - Finance
Age: 62
Bio & Compensation  - Reuters
Fady I. Malik M.D. Ph.D. Executive Vice President - Research and Development
Age: 52
Bio & Compensation  - Reuters
Peter S. Roddy Senior Vice President, Chief Accounting Officer
Age: 57
Bio & Compensation  - Reuters
David W. Cragg Senior Vice President - Human Resources
Age: 61
Bio & Compensation  - Reuters
Bonnie A. Charpentier Ph.D. Senior Vice President - Regulatory Affairs and Compliance
Age: 65
Bio & Compensation  - Reuters
Bradley Paul Morgan Ph.D. Senior Vice President - Research and Non-Clinical Development
Age: 56
Bio & Compensation  - Reuters
Elisabeth Schnieders Ph.D. Senior Vice President - Business Development
Age: 50
Bio & Compensation  - Reuters